MedCity News January 18, 2022
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company’s goal of translating insights from genomics data and analytics into making precision medicine a standard of care.
Sema4 announced Tuesday that it’s acquiring GeneDx in a move the health intelligence company expects will enhance its data-driven insights and improve its market position in women’s health and the diagnosis of rare diseases.
The deal between Stamford, Connecticut-based Sema4 and GeneDx’s parent, Miami-based OPKO Health, also brought in $200 million in a private transaction from growth and life sciences investors, including Pfizer that will strengthen Sema4’s balance sheet.
In a news release, the newly combined company projected it would be...
Today's Sponsors
Today's Sponsor